Glenmark commences Phase II study of GBR 500 for ulcerative colitis
The randomised, double-blind, placebo-controlled study will evaluate the efficacy and safety of GBR 500 in patients with moderate to severe UC. Glenmark Pharmaceuticals chief scientific officer Dr. Michael
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.